DODAC

1: Havlíková M, Jugl A, Krouská J, Szabová J, Mravcová L, Venerová T, Chang CH, Pekař M, Mravec F. Interactions between Cationic Ion Pair Amphiphile Vesicles and Hyaluronan-A Physicochemical Study. Langmuir. 2021 Jul 20;37(28):8525-8533. doi: 10.1021/acs.langmuir.1c00993. Epub 2021 Jul 2. PMID: 34214390. 2: Gonçalves RA, Lam YM, Lindman B. Double-Chain Cationic Surfactants: Swelling, Structure, Phase Transitions and Additive Effects. Molecules. 2021 Jun 28;26(13):3946. doi: 10.3390/molecules26133946. PMID: 34203337; PMCID: PMC8271693. 3: Rusli W, van Herk AM. Effect of salts on size and morphology of extruded dimethyldioctadecylammonium bromide or chloride vesicle for polymeric nanocapsules synthesis via templating emulsion polymerization. J Colloid Interface Sci. 2021 Apr;587:393-401. doi: 10.1016/j.jcis.2020.11.116. Epub 2020 Dec 25. PMID: 33370661. 4: Hishida M, Shimokawa N, Okubo Y, Taguchi S, Yamamura Y, Saito K. Phase Transition from the Interdigitated to Bilayer Membrane of a Cationic Surfactant Induced by Addition of Hydrophobic Molecules. Langmuir. 2020 Dec 8;36(48):14699-14709. doi: 10.1021/acs.langmuir.0c02609. Epub 2020 Nov 24. PMID: 33232164. 5: Khattab MH, Weaver M, Cook C, Kinder N, Vassar M. Public Speaker Characteristics at Meetings of the Dermatologic and Ophthalmic Drug Advisory Committee and the Ophthalmic Devices Panel. Am J Ophthalmol. 2021 Mar;223:28-32. doi: 10.1016/j.ajo.2020.09.043. Epub 2020 Nov 6. PMID: 33166500. 6: Luna ACL, Saraiva GKV, Chierice GO, Hesse H, Maria DA. Antiproliferative and proapoptotic effects of DODAC/synthetic phosphoethanolamine on hepatocellular carcinoma cells. BMC Pharmacol Toxicol. 2018 Jul 11;19(1):44. doi: 10.1186/s40360-018-0225-2. PMID: 29996919; PMCID: PMC6042440. 7: Oliveira ACN, Fernandes J, Gonçalves A, Gomes AC, Oliveira MECDR. Lipid-based Nanocarriers for siRNA Delivery: Challenges, Strategies and the Lessons Learned from the DODAX: MO Liposomal System. Curr Drug Targets. 2019;20(1):29-50. doi: 10.2174/1389450119666180703145410. PMID: 29968536. 8: Gonçalves RA, Lindman B, Miguel MG, Iwata T, Lam YM. Elucidating the effect of additives on the alkyl chain packing of a double tail cationic surfactant. J Colloid Interface Sci. 2018 Oct 15;528:400-409. doi: 10.1016/j.jcis.2018.05.092. Epub 2018 May 26. PMID: 29879617. 9: Luna ACL, Santos Filho JRA, Hesse H, Neto SC, Chierice GO, Maria DA. Modulation of pro-apoptotic effects and mitochondrial potential on B16F10 cells by DODAC/PHO-S liposomes. BMC Res Notes. 2018 Feb 14;11(1):126. doi: 10.1186/s13104-018-3170-7. PMID: 29444697; PMCID: PMC5813323. 10: Wang G, Miao Y, Sun Z, Zheng S. Simultaneous adsorption of aflatoxin B1 and zearalenone by mono- and di-alkyl cationic surfactants modified montmorillonites. J Colloid Interface Sci. 2018 Feb 1;511:67-76. doi: 10.1016/j.jcis.2017.09.074. Epub 2017 Sep 25. PMID: 28972897. 11: Rezaee M, Oskuee RK, Nassirli H, Malaekeh-Nikouei B. Progress in the development of lipopolyplexes as efficient non-viral gene delivery systems. J Control Release. 2016 Aug 28;236:1-14. doi: 10.1016/j.jconrel.2016.06.023. Epub 2016 Jun 15. PMID: 27317365. 12: Oliveira ACN, Sárria MP, Moreira P, Fernandes J, Castro L, Lopes I, Côrte- Real M, Cavaco-Paulo A, Real Oliveira MECD, Gomes AC. Counter ions and constituents combination affect DODAX : MO nanocarriers toxicity in vitro and in vivo. Toxicol Res (Camb). 2016 Jun 13;5(4):1244-1255. doi: 10.1039/c6tx00074f. PMID: 30090429; PMCID: PMC6062248. 13: Luna AC, Saraiva GK, Filho OM, Chierice GO, Neto SC, Cuccovia IM, Maria DA. Potential antitumor activity of novel DODAC/PHO-S liposomes. Int J Nanomedicine. 2016 Apr 18;11:1577-91. doi: 10.2147/IJN.S90850. PMID: 27143880; PMCID: PMC4841408. 14: Lopes I, C N Oliveira A, P Sárria M, P Neves Silva J, Gonçalves O, Gomes AC, Real Oliveira ME. Monoolein-based nanocarriers for enhanced folate receptor- mediated RNA delivery to cancer cells. J Liposome Res. 2016 Sep;26(3):199-210. doi: 10.3109/08982104.2015.1076463. Epub 2015 Aug 17. PMID: 26340109. 15: Shin MJ, Kim YJ, Kim JD. Chromatic response of polydiacetylene vesicle induced by the permeation of methotrexate. Soft Matter. 2015 Jul 7;11(25):5037-43. doi: 10.1039/c5sm00925a. Erratum in: Soft Matter. 2015 Sep 14;11(34):6903-4. PMID: 26016992. 16: Park CY, Kim MW. Dynamic mechanical properties of a polyelectrolyte adsorbed insoluble lipid monolayer at the air-water interface. J Phys Chem B. 2015 Apr 23;119(16):5315-20. doi: 10.1021/jp5123773. Epub 2015 Apr 14. PMID: 25826703. 17: Nakamura A, Endo H, Yamashita T, Kawai T. Sodium dodecylsulfate bilayer formation under a cationic surfactant Langmuir monolayer at the air-water interface. J Nanosci Nanotechnol. 2014 Mar;14(3):2198-203. doi: 10.1166/jnn.2014.8522. PMID: 24745212. 18: Oliveira AC, Martens TF, Raemdonck K, Adati RD, Feitosa E, Botelho C, Gomes AC, Braeckmans K, Real Oliveira ME. Dioctadecyldimethylammonium:monoolein nanocarriers for efficient in vitro gene silencing. ACS Appl Mater Interfaces. 2014 May 14;6(9):6977-89. doi: 10.1021/am500793y. Epub 2014 Apr 18. PMID: 24712543. 19: Sabatino P, Choudhury RP, Schönhoff M, Van der Meeren P, Martins JC. NMR investigation of exchange dynamics and binding of phenol and phenolate in DODAC vesicular dispersions. J Phys Chem B. 2012 Aug 2;116(30):9269-76. doi: 10.1021/jp304749g. Epub 2012 Jul 12. PMID: 22731738. 20: Woiterski L, Britt DW, Käs JA, Selle C. Oriented confined water induced by cationic lipids. Langmuir. 2012 Mar 13;28(10):4712-22. doi: 10.1021/la205043x. Epub 2012 Mar 1. PMID: 22339557.

C38H76CLN

582.483

581.57

C, 78.36; H, 13.15; Cl, 6.09; N, 2.40

7212-69-3

7212-69-3 (chloride);45315-43-3 (cation);

CCCCCCCC/C=C\CCCCCCCC[N+](C)(C)CCCCCCCC/C=C\CCCCCCCC.[Cl-]

UAKOZKUVZRMOFN-JDVCJPALSA-M

InChI=1S/C38H76N.ClH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h19-22H,5-18,23-38H2,1-4H3;1H/q+1;/p-1/b21-19-,22-20-;

(Z)-N,N-dimethyl-N-((Z)-octadec-9-en-1-yl)octadec-9-en-1-aminium chloride

DODAC; Adogen 472; Arquad 20-75I; Cation 2OLR; Dimethyldioleylammonium chloride; Dioleyldimethylammonium chloride; Lipoquad 20-75I; N,N-Dioleyl-N,N-dimethylammonium chloride; Nissan Cation 2OLR; Soft and Dry

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

注意: 如下所列的是一些常用的体内动物实验溶解配方，主要用于溶解难溶或不溶于水的产品（水溶度<1 mg/mL）。 建议您先取少量样品进行尝试，如该配方可行，再根据实验需求增加样品量。

---

注射用配方1: DMSO : Tween 80： Saline = 10 : 5 : 85 (如： 100 μL DMSO → 50 μL Tween 80 → 850 μL Saline)
*生理盐水/Saline的制备：将0.9g氯化钠/NaCl溶解在100 mL ddH ₂ O中，得到澄清溶液。
注射用配方 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL DMSO → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)
注射用配方 3: DMSO : Corn oil = 10 : 90 (如： 100 μL DMSO → 900 μL Corn oil)
示例: 以注射用配方 3 (DMSO : Corn oil = 10 : 90) 为例说明, 如果要配制 1 mL 2.5 mg/mL的工作液, 您可以取 100 μL 25 mg/mL 澄清的 DMSO 储备液，加到 900 μL Corn oil/玉米油中, 混合均匀。

View More

注射用配方 4: DMSO : 20% SBE-β-CD in Saline = 10 : 90 [如：100 μL DMSO → 900 μL (20% SBE-β-CD in Saline)]
*20% SBE-β-CD in Saline的制备（4°C，储存1周）：将2g SBE-β-CD (磺丁基-β-环糊精) 溶解于10mL生理盐水中，得到澄清溶液。
注射用配方 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (如： 500 μL 2-Hydroxypropyl-β-cyclodextrin (羟丙基环胡精)→ 500 μL Saline)
注射用配方 6: DMSO : PEG300 : Castor oil : Saline = 5 : 10 : 20 : 65 (如： 50 μL DMSO → 100 μL PEG300 → 200 μL Castor oil → 650 μL Saline)
注射用配方 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (如： 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
注射用配方 8: 溶解于Cremophor/Ethanol (50 : 50), 然后用生理盐水稀释。
注射用配方 9: EtOH : Corn oil = 10 : 90 (如： 100 μL EtOH → 900 μL Corn oil)
注射用配方 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (如： 100 μL EtOH → 400 μL PEG300 → 50 μL Tween 80 → 450 μL Saline)

---

口服配方 1: 悬浮于0.5% CMC Na (羧甲基纤维素钠)
口服配方 2: 悬浮于0.5% Carboxymethyl cellulose (羧甲基纤维素)
示例: 以口服配方 1 (悬浮于 0.5% CMC Na)为例说明, 如果要配制 100 mL 2.5 mg/mL 的工作液, 您可以先取0.5g CMC Na并将其溶解于100mL ddH2O中，得到0.5%CMC-Na澄清溶液；然后将250 mg待测化合物加到100 mL前述 0.5%CMC Na溶液中，得到悬浮液。

View More

口服配方 3: 溶解于 PEG400 (聚乙二醇400)
口服配方 4: 悬浮于0.2% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 5: 溶解于0.25% Tween 80 and 0.5% Carboxymethyl cellulose (羧甲基纤维素)
口服配方 6: 做成粉末与食物混合

---

注意: 以上为较为常见方法，仅供参考， InvivoChem并未独立验证这些配方的准确性。具体溶剂的选择首先应参照文献已报道溶解方法、配方或剂型，对于某些尚未有文献报道溶解方法的化合物，需通过前期实验来确定（建议先取少量样品进行尝试），包括产品的溶解情况、梯度设置、动物的耐受性等。

---

请根据您的实验动物和给药方式选择适当的溶解配方/方案：
1、请先配制澄清的储备液(如：用DMSO配置50 或 100 mg/mL母液(储备液));
2、取适量母液，按从左到右的顺序依次添加助溶剂，澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明，并不一定代表此产品 的实际溶解配方):
10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline);
假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀/澄清；向上述体系中加入50 μL Tween-80，混合均匀/澄清；然后继续加入450 μL ddH2O (或 saline)定容至 1 mL；
3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例;
4、 如产品在配制过程中出现沉淀/析出，可通过加热(≤50℃)或超声的方式助溶;
5、为保证最佳实验结果，工作液请现配现用！
6、如不确定怎么将母液配置成体内动物实验的工作液，请查看说明书或联系我们;
7、 以上所有助溶剂都可在 Invivochem.cn网站购买。